Serina Therapeutics, Inc. (SER): debt financing — AgeX draws remaining $500K under secured note with Juvenescence; repayment due Feb 14, 2024

Serina Therapeutics, Inc.

Drew $500,000 from Amended Secured Convertible Promissory Note on Oct 31, 2023.
Repayment date for outstanding principal is February 14, 2024.
Negotiating an increase in the Secured Note line of credit with Juvenescence.
Previously disclosed material terms in 10-Q filed May 12, 2023 and 8-Ks filed June 8 and Aug 4, 2023.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.92

Serina Therapeutics, Inc. incurred credit facility of $500,000 with Juvenescence Limited at not disclosed maturing February 14, 2024.

Instrument: credit facility
Principal: $500,000
Counterparty: Juvenescence Limited
Rate: not disclosed
Maturity: February 14, 2024
Event: incurrence

Exact text from the filing

On October 31, 2023, AgeX drew the remaining $500,000 of its credit available under the Amended and Restated Secured Convertible Promissory Note, as amended, (“Secured Note”) with Juvenescence Limited (“Juvenescence”).

View on SEC.gov

Browse all debt financings →

Serina Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-039514

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.